Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 in Patients With Mild or General COVID-19
NCT05075304Phase 1Terminated
- Sponsor
- Staidson Biopharmaceutical
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BDB-001 in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Staidson Biopharmaceutical. Primary endpoints: Number of participants with serious adverse events (SAEs) and non-serious adverse events, Number of participants with abnormal laboratory tests and 5 more. Started Feb 2020; status: terminated.
02
Drugs
BDB-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05075304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075304.